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AbstrAct
Objective
To characterise the symptoms of coronavirus disease 
2019 (covid-19).
Design




All individuals who tested positive for severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) 
by reverse transcription polymerase chain reaction 
(RT-PCR) between 17 March and 30 April 2020. Cases 
were identified by three testing strategies: targeted 
testing guided by clinical suspicion, open invitation 
population screening based on self referral, and 
random population screening. All identified cases 
were enrolled in a telehealth monitoring service, 
and symptoms were systematically monitored from 
diagnosis to recovery.
Main OutcOMe Measures
Occurrence of one or more of 19 predefined symptoms 
during follow-up.
results
Among 1564 people positive for SARS-CoV-2, the 
most common presenting symptoms were myalgia 
(55%), headache (51%), and non-productive cough 
(49%). At the time of diagnosis, 83 (5.3%) individuals 
reported no symptoms, of whom 49 (59%) remained 
asymptomatic during follow-up. At diagnosis, 216 
(14%) and 349 (22%) people did not meet the 
case definition of the Centers for Disease Control 
and Prevention and the World Health Organization, 
respectively. Most (67%) of the SARS-CoV-2-positive 
patients had mild symptoms throughout the course of 
their disease.
cOnclusiOn
In the setting of broad access to RT-PCR testing, 
most SARS-CoV-2-positive people were found to 
have mild symptoms. Fever and dyspnoea were less 
common than previously reported. A substantial 
proportion of SARS-CoV-2-positive people did not 
meet recommended case definitions at the time of 
diagnosis.
Introduction
On 31 December 2019, the first cases of an atypi­
cal pneumonia of unidentified aetiology were 
reported in Wuhan, China.1 One week later, a novel 
betacoronavirus, later named severe acute respiratory 
syndrome coronavirus (SARS­CoV­2), was identified 
as the causative pathogen,2 3 and the disease sub­
sequently termed coronavirus disease 2019 (covid­19). 
The World Health Organization (WHO) declared the 
covid­19 outbreak a pandemic on 11 March 2020.4
Covid­19 has a wide range of clinical manifestations, 
ranging from an asymptomatic state or mild respira­
tory symptoms to severe viral pneumonia and 
acute respiratory distress syndrome.5­7 Previous 
publications have suggested that, among identified 
symptomatic cases, approximately 81% have mild 
symptoms, 14% have severe symptoms, and 5% 
become critically ill.8 Besides respiratory symptoms, 
dysosmia, dysgeusia, abdominal pain, diarrhoea, and 
rash have been described.5 9 Most published studies on 
the clinical characteristics of covid­19 have been retro 
spective5 8 10 11 and limited to inpatients12 13 and 
therefore do not capture the full clinical spectrum of 
the disease.
The first case of covid­19 in Iceland was diagnosed 
on 27 February 2020.14 Icelandic health authorities 
responded immediately by isolating infected people 
and instituting systematic contact tracing and 
quarantine of exposed individuals.15 Broad access 
to real­time reverse transcriptase polymerase chain 
reaction (RT­PCR) testing became available in Iceland 
early in the course of the pandemic, resulting in one 
of the highest rates of SARS­CoV­2 testing in the 
world.16 Approximately one month after the first case 
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WhAt Is AlreAdy knoWn on thIs topIc
The symptoms of SARS-CoV-2 infection are predominantly respiratory in nature 
with fever, cough, and sore throat being commonly reported, and loss of smell 
and taste identified as more specific symptoms
However, most studies describing the symptomatology have been limited to 
patients who required hospital admission and often ascertained symptoms only 
at a single point in time
WhAt thIs study Adds
In this population based cohort, common presenting symptoms of SARS-CoV-2 
included myalgia (55%), headache (51%), and non-productive cough (49%)
Most infected individuals had mild symptoms. At diagnosis, 14% did not meet 
the Centers for Disease Control and Prevention case definition for suspected 
covid-19, and 22% did not meet the World Health Organization definition
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was identified in Iceland, the incidence of undetected 
SARS­CoV­2 infections was found to be only 0.6% 
by random population screening using RT­PCR.14 
A subsequent study found that only 56% of indivi­ 
duals positive for SARS­CoV­2 antibodies had been 
diagnosed by RT­PCR.17 All SARS­CoV­2­positive 
individuals were actively monitored at a newly esta­
blished covid­19 outpatient clinic at Landspitali–The 
National University Hospital (LUH).15 18 The contact 
tracing and containment strategies implemented by 
the Icelandic authorities rapidly curbed the epidemic, 
with only 12 new cases diagnosed between 1 May and 
15 June.14
In this paper, we describe the analysis of prospectively 
collected data on all people who tested positive for 
SARS­CoV­2 by RT­PCR in Iceland and characterise the 
epidemiology and full clinical spectrum of covid­19 in 
this nationwide cohort.
Methods
study population and design
This population based cohort study included all 
people who tested positive for SARS­CoV­2 by RT­
PCR between 27 February and 30 April 2020 and 
were actively monitored at LUH. All individuals in 
Iceland who tested positive for SARS­CoV­2 were 
immediately contacted, instructed to isolate, and 
enrolled in a telehealth monitoring service. Monitoring 
involved frequent telephone interviews by a nurse or 
physician, through which the patient’s clinical status 
was evaluated. From 27 February to 16 March 2020, 
the content and documentation of these interviews 
was at the discretion of the nurse or physician making 
the call. On 17 March, a standardised data entry form 
was built directly into the national electronic medical 
record system, facilitating a structured approach to the 
clinical evaluation of patients with covid­19. The study 
was approved by the National Bioethics Committee 
(VSN­20­078).
virological testing
RT­PCR was used for detection of SARS­CoV­2 RNA 
in nasopharyngeal and oropharyngeal swabs, based 
on the WHO recommended protocol from Charité, 
Berlin,19 or using a commercial kit (TaqMan 2019­nCoV 
Assay from Thermo Fisher Scientific) as previously 
described.15 Three testing protocols were implemented: 
targeted testing, open invitation population screening, 
and random population screening. Targeted testing was 
performed at LUH, whereas population screening was 
carried out by deCODE genetics, a biopharmaceutical 
company based in Reykjavik.15 Targeted testing began 
on 31 January 2020 and included clinically suspected 
cases and individuals at high risk of exposure, though 
exposure was not a requirement for testing. Open 
invitation population screening began on 13 March 
2020 and was available to all Icelandic residents who 
were not in quarantine and did not have symptoms that 
prompted targeted testing. Finally, a randomly chosen 
sample of 6782 Icelanders was offered testing via 
telephone text message on 31 March and 1 April 2020.
Data collection
To confirm the completeness of telehealth enrolment, 
results of all SARS­CoV­2 testing were obtained from 
databases of LUH and deCODE genetics. Negative 
samples were used for denominator calculations. 
Baseline characteristics of SARS­CoV­2­positive pati­
ents and longitudinal data on symptom progression 
until 22 May were obtained from the standardised 
data entry forms used by the covid­19 clinic. Data on 
clinical outcomes were extracted from LUH database. 
Data were linked using government issued national 
identification numbers. Population demographics 
were obtained from Statistics Iceland (https://www.
statice.is/).
telehealth monitoring service
The initial patient interviews were conducted by a 
physician who informed the patients of the diagnosis, 
evaluated their health, and instructed them to self 
isolate at home. A checklist of 19 specific symptoms 
was used during the initial and all subsequent 
interviews. The list of symptoms was developed based 
on findings reported in the literature at the time when 
the telehealth monitoring was being launched and 
with respect to symptoms reported by the first 200 
Icelanders who contracted covid­19. The list was 
subsequently refined, taking into account symptoms 
described by patients during the early interviews 
and was formally introduced on 17 March. From this 
point onwards the checklist remained unchanged. 
Furthermore, the patients were asked during every 
interview if additional symptoms were present. Finally, 
the patients’ baseline characteristics were documented, 
including past medical history, medication use, and 
social history.
Based on the symptoms documented during the 
interviews, patients were classified into one of three 
categories of clinical severity: low severity (defined 
as mild and improving symptoms); moderate severity 
(mild dyspnoea, cough, or fever for less than five days); 
and high severity (worsening dyspnoea, worsening 
cough, high or persistent fever for five days or longer, 
or lethargy). The frequency of follow­up interviews 
ranged from daily to every fourth day depending on 
clinical severity, age, and underlying conditions. 
Patients with concerning symptoms were referred for 
evaluation at the covid­19 clinic.
Patients were released from isolation and dis­
charged from telehealth monitoring when they met 
both of the following criteria: 14 days had passed 
since the diagnosis of covid­19, and they had been 
asymptomatic for the past seven consecutive days.
case definitions
Patients were considered symptomatic due to covid­19 
using three different definitions: (a) reporting at least 
one of the 19 symptoms; (b) WHO case definition of 
suspected covid­19, which included fever and at least 
one other symptom of acute respiratory infection, 
such as cough or shortness of breath20; (c) Centers 
for Disease Control and Prevention (CDC) interim 
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case definition of covid­19, which included either 
two of the following symptoms—fever, rigor, myalgia, 
headache, sore throat, dysosmia, dysgeusia—or one of 
the following symptoms—cough, shortness of breath, 
difficulty breathing.21 Individuals who did not fulfill 
these definitions at the time of diagnosis or during 
follow­up were determined to be asymptomatic. 
Otherwise, they were considered presymptomatic at 
the time of diagnosis.
statistical analysis
The incidence of covid­19 was calculated by age and 
sex, using both the Icelandic population and all SARS­
CoV­2 tested individuals as denominators. Patients 
were followed until discharge from the telehealth 
monitoring service, hospital admission, death, or end 
of the study period (22 May 2020). Patients enrolled 
before the implementation of the standardised data 
entry form (17 March 2020) were excluded from the 
analysis of symptoms and symptom progression.
The progression of covid­19 symptoms was analysed 
using parametric cure­mixture models and logistic 
regression. The time frame used in the analyses was 
days from symptom onset to discharge from telehealth 
monitoring. The data were interval censored due to the 
intermittent schedule of the interviews. To account for 
this, the cumulative incidence of symptom occurrence 
was estimated with the non­parametric Turnbull esti­
mator and a parametric cure­mixture model using the 
log­logistic distribution. The proportion of patients 
experiencing a specific symptom per day was estimated 
employing logistic regression that allowed for non­
linear effects using a three­knot restricted cubic spline. 
Missing information between interviews was addressed 
by multiple imputation using chained equations, per­
formed with additive regression, bootstrapping and 
predictive mean matching procedure.22 The number of 
imputations equaled the highest proportion of missing 
data for any variable multiplied by 100. The added 
uncertainty due to imputation was fully accounted 
for in the logistic regression models. The result was 
compared with a complete­case analysis and naive up­
down filling procedure. All statistical analyses were 
performed in R version 3.6.3.
Patient and public involvement
Neither patients nor the public were involved in the 
design, conduct, reporting, or dissemination planning 
of the study. Members of the research team were 
instrumental in creating and implementing the local 
response to the pandemic and were involved in care of 
patients with covid­19. The urgency of designing and 
conducting the research precluded patient or public 
involvement.
results
Demographics and clinical characteristics
A total of 45 105 individuals (12% of the Icelandic 
population) underwent 47 800 RT­PCR tests for SARS­
CoV­2 from 31 January to 30 April 2020. Of those, 
16 750 (37%) underwent targeted testing, 26 762 
(59%) participated in open invitation population 
screening, and 3924 (8.7%) in random population 
screening (fig 1). A small proportion of people (3.5%) 
were tested by more than one of the three testing 
strategies. No individual tested positive by more than 
one testing strategy. The participation rate in random 
screening among the 6782 people invited was 56%. 
The population incidence of SARS­CoV­2­positive 
people was 4.9 per 1000 individuals, and 39 per 1000 
individuals tested were positive. This rate differed 
between the three testing strategies; the rate was 96 
per 1000 individuals who underwent targeted testing, 
5.9 per 1000 tested in open invitation population 
screening, and 5.1 per 1000 tested in random 
population screening.
All people who tested positive were enrolled in 
telehealth monitoring or admitted to hospital, with no 
exceptions. The median time from symptom onset until 
RT­PCR diagnosis and the enrolment interview was 
four days (interquartile range (IQR) 2­7 days), and a 
median of six (IQR 4­8) interviews were conducted per 
individual during telehealth monitoring. The median 
time between interviews was two days (IQR 1­3). The 
clinical progression from symptom onset for the 1797 
positive individuals is shown in figure 2. Thirty two of 
those patients were diagnosed after being admitted 
to hospital, of whom one was diagnosed post mortem 
(fig 1). Table 1 shows the characteristics of the SARS­
CoV­2­positive cohort categorised by testing strategy. 
We did not identify differences in relevant baseline 
characteristics between individuals diagnosed by 
targeted testing, open invitation population screening, 
or random population screening. However, the small 
size of the groups representing some of these features 
precludes meaningful analysis. Of the 1797 SARS­CoV­
2­positive individuals, 101 (5.6%) were admitted to 
hospital, 27 (1.5%) were admitted to an intensive care 
unit, and 16 (0.9%) required mechanical ventilation. 
The median length of hospital stay was 8 days (IQR 
3.5­19), and 10 (0.6%) patients died. The total number 
of documented symptoms at diagnosis was lower 
among people diagnosed before the implementation 
of standardised symptom monitoring compared 
with those diagnosed after the implementation 
(supplemental fig S1 on bmj.com). The latter group 
was therefore used to study symptom development 
and progression (fig 1).
Of the 1564 (87%) people who were followed using 
the standardised data entry form, 791 (51%) were 
female and their median age was 40 years (IQR 26­
53, range 0­103). Among these 1564 people, 1055 
(67%) were classified as having low disease severity 
throughout the follow­up period, 55 (3.5%) were 
admitted to hospital, and 13 (0.8%) required intensive 
care, with six (0.4%) also receiving mechanical 
ventilation. Two (0.1%) patients died. The median 
follow­up was 15 days (IQR 14­18), resulting in 
69.2 person­years of follow­up time. A total of 1509 
people completed the telehealth follow­up from 
diagnosis until discharge. The observation time of the 
remaining 55 patients who were admitted to hospital 
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was censored at the time of admission, after a median 
follow­up of four days (IQR 2.5­8).
symptoms at diagnosis
Of the 1564 people with standardised symptom 
documentation, 668 (43%) had experienced fever at 
diagnosis. Cough (n=940, 60%), dyspnoea (n=496, 
32%), and gastrointestinal symptoms (n=558, 36%) 
were also commonly reported. Eighty three (5.3%) 
people reported no symptoms at diagnosis, which 
was more commonly noted among those diagno­
sed through open invitation population screening 
(n=32/135, 24%) and random population screening 
(n=6/20, 30%), than among individuals diagnosed by 
targeted testing (n=45/1409, 3.2%). Of the 83 people 
who were asymptomatic at diagnosis, 49 (59%) did 
not develop any symptoms throughout the telehealth 
monitoring, while the remaining 34 (41%) developed 
symptoms after a median of three days (IQR 3­4.75). 
All people diagnosed by random population screening 
who were asymptomatic at diagnosis remained so 
during follow­up, compared with 19 of 32 (59%) 
individuals identified by open invitation population 
screening and 24 of 45 (53%) diagnosed by targeted 
testing.
Using the CDC case definition, the symptoms 
reported by 216 of 1564 (14%) SARS­CoV­2­positive 
people were not consistent with covid­19 at the time 
of diagnosis. This was more common among indivi­
duals diagnosed through open invitation population 
screening (n=54/135, 40%) and random population 
screening (n=9/20, 45%), than by targeted testing 
(n=153/1409, 11%). Seventy two (33%) of those 
people developed symptoms compatible with the CDC 
case definition at a median of five days (IQR 3­6) from 
diagnosis, whereas the other 144 (67%) never met the 
CDC criteria. Similarly, 349 of 1564 (22%) individuals 
did not fulfill the WHO case definition at the time of 
diagnosis, a finding that was more commonly observed 
among those diagnosed through open invitation 
population screening (n=59/135, 44%) and random 
population screening (n=12/20, 60%), than by 
targeted testing (n=278/1409, 20%). The WHO criteria 
were later met by 115 (33%) individuals at a median of 
four days (IQR 3­6) from diagnosis, while the remaining 
234 (67%) people never fulfilled the criteria.
The cumulative incidence and proportion of infected 
individuals meeting CDC and WHO criteria by number 
of days from symptom onset is shown in supplemental 
figure S2 on bmj.com. Among the 216 individuals who 
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Fig 1 | Flowchart describing the derivation of the study cohort
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did not meet CDC criteria at diagnosis, four (1.9%) 
were admitted to hospital later in the course of their 
disease, and one required mechanical ventilation. 
Similarly, four (1.1%) of the 349 individuals who did 
not fulfill the WHO criteria at diagnosis were admitted 
to hospital for illness related to covid­19, two of whom 
required intensive care. Among the 372 people who did 
not have symptoms consistent with WHO or with CDC 
criteria at diagnosis, the most common symptoms were 
headache (n=140, 38%), rhinorrhoea (n=128, 34%), 
dysosmia (n=123, 33%), and dysgeusia (n=122, 33%), 
with 241 (65%) individuals experiencing at least one 
of these symptoms.
symptoms at disease onset
As shown in table 2, the most common symptoms 
at the onset of covid­19 were myalgia (54.6% (95% 
CI 50.6% to 58.6%)), headache (51.2% (46.8% to 
55.7%)), and non­productive cough (49.3% (45.2% 
to 53.3%)). Overall, 83.0% (80.6% to 85.1%) of 
individuals experienced at least one generalised 
symptom and 62.9% (59.1% to 66.6%) at least one 
upper respiratory symptom. Multiple imputation 
logistic regression produced acceptable results as 
compared with complete case analysis and a naive 
up­down filling procedure (supplemental figs S3­
S6). Symptoms occurring on days when interviews 
were not conducted were imputed. The proportion of 
people with missing information on symptoms was 
highest during the first days following symptom onset 
(supplemental table S1).
Compared with people diagnosed by targeted 
testing, those diagnosed through either open invitation 
or random population screening were less likely to 
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Fig 2 | changes in severity of symptoms from onset to end of follow-up among sars-cov-2-positive individuals. the category “not yet diagnosed” 
comprises people yet to be enrolled in telehealth monitoring, and whose clinical severity had therefore not been evaluated. the severity of 
symptoms was categorised as low (mild and improving symptoms), moderate (mild dyspnoea, cough, or fever for less than 5 days), or high 
(worsening dyspnoea, worsening cough, high or persistent fever for 5 days or longer, or lethargy). the top panel includes all sars-cov-2-positive 
people. the other panels show people categorised by age; 0-9, 10-19, 20-39, 40-64, and ≥65 years
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have experienced cardinal symptoms of covid­19 
at disease onset, including fever (635/1409 (45%) 
v 33/155 (21%)), cough (877 (62%) v 63 (41%)), 
dyspnoea (473 (34%) v 23 (15%)) and gastrointestinal 
symptoms (530 (38%) v 28 (18%)). Other symptoms 
categorised according to testing strategy are shown in 
supplemental figures S7­S10.
The proportion of patients experiencing specific 
symptoms by sex and age group is displayed in 
supplemental figures S11­S14. The initial presentation 
of covid­19 varied only slightly between the sexes. 
The proportion experiencing fever or gastrointestinal 
symptoms at onset was similar between age groups, 
but cough and dyspnoea were more common among 
older individuals (supplemental fig S13).
Differences in symptoms at onset between patients 
who were admitted to hospital and those who were 
not are shown in supplemental figures S15­S18. 
Symptoms at disease onset were more common among 
patients who were later admitted to hospital, including 
generalised symptoms (94% v 83%), lower respiratory 
symptoms (70% v 63%), and gastrointestinal 
symptoms (48% v 29%). However, the proportion of 
patients who experienced upper respiratory symptoms 
was lower, 48% compared with 64% of those who were 
never admitted to hospital.
Progression of symptoms
By day 21 from disease onset, the most commonly 
experienced symptoms were lethargy (74.7% (95% 
CI 72.5% to 76.9%)), headache (73.0% (70.6% to 
75.2%)), and productive or non­productive cough 
(72.8% (70.2% to 75.1%)). Overall, 93.1% (91.6% 
to 94.3%) had experienced at least one generalised 
symptom, 87.2% (85.2% to 88.8%) at least one upper 
respiratory symptom, and 80.3% (78.2% to 82.3%) at 
least one lower respiratory symptom. The cumulative 
incidence of fever, dyspnoea, and gastrointestinal 
symptoms by day 21 were 47.8%, 52.0%, and 
50.1%, respectively (fig 3). Of those who eventually 
developed fever, 85.2% had done so by the third day 
of their illness. Similarly, 80.2% had experienced 
cough, 52.2% dyspnoea, and 62.0% gastrointestinal 
symptoms by day three. The proportion of people 
who had developed each symptom was comparable 
regardless of sex or age group (supplemental figures 
S19­S30).
Of the 19 symptoms, only dysosmia and dysgeusia 
were more common later in the disease course than 
at symptom onset. Both symptoms peaked on day 
eight from diagnosis. The trend was most pronounced 
among individuals aged 25 to 55 years and was more 
marked among females (supplemental fig S12). Other 
symptoms attributed to covid­19 were most prevalent 
during the onset of the disease. No symptom exhibited 
a bimodal pattern (supplemental figs S11­S14). The 
cumulative incidence of each specific symptom was 
lower among people diagnosed through population 
screening compared with targeted testing, except for 
rhinorrhea and vomiting (supplemental figs S31­S34). 
By day 21, a large proportion of patients who were 
ever admitted to hospital for covid­19 had experienced 
cough (96.0% (95% CI 76.3% to 98.4%)), fever (91.0% 
(68.6% to 95.7%)), gastrointestinal symptoms (84.8% 
(64.7% to 91.5%)), and dyspnoea (82.7% (65.7% to 
91.1%)) (supplemental figs S35­S38).
discussion
In this study, we examined the clinical characteristics 
of covid­19 among people diagnosed by RT­PCR in a 
national population based cohort. Our prospectively 
collected data on symptoms and disease progression 
revealed that 73% experienced cough, 52% dyspnoea, 
and 48% fever. At the time of diagnosis, 5% were 
completely asymptomatic, 14% did not meet the CDC 
case definition for covid­19, and 22% did not fulfill 
the WHO criteria. Due to aggressive contact tracing 
and widespread virological testing it is likely that the 
cohort includes the majority of symptomatic cases in 
the population. This assumption is supported by the 
low prevalence of SARS­CoV­2 infection detected by 
random population screening using RT­PCR during the 
table 1 | characteristics of sars-cov-2-positive individuals according to testing strategy
targeted testing Open population screening random population screening
No of people 1619 158 20
Median (IQR) age (years) 42.0 (26.0-55.0) 39.0 (29.0-49.0) 45.0 (33.75-54.75)
No (%) of females 822 (50.8) 72 (45.6) 9 (45.0)
Median (IQR) body mass index 24.5 (22.6-29.6) 27.5 (23.6-30.9) 27.6 (24.5-31.2)
No (%) of people with:
 Lung disease 237 (14.6) 22 (13.9) 1 (5.0)
 Diabetes 71 (4.4) 3 (1.9) 1 (5.0)
 Hypertension 254 (15.7) 19 (12.0) 4 (20.0)
 Cardiovascular disease 141 (8.7) 6 (3.8) 1 (5.0)
 Chronic kidney disease 36 (2.2) 1 (0.6) 1 (5.0)
 Cancer 81 (5.0) 4 (2.5) 0
 Current smoking 77 (4.8) 7 (4.4) 2 (10.0)
Clinical severity of covid-19 at enrolment (No (%)):
 Low 1276 (78.8) 147 (93.0) 19 (95)
 Moderate 227 (14.0) 6 (3.8) 1 (5.0)
 High 68 (4.2) 2 (1.3) 0
Hospital admission (No (%)) 100 (6.2) 1 (0.6) 0
Admisison to intensive care unit (No (%)) 27 (1.7) 0 0
IQR=interquartile range.
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peak of the epidemic (0.6%),15 and by a subsequent 
population based study estimating that 56% of 
seropositive people had previously been diagnosed by 
RT­PCR.17
The comprehensive, nationwide characterisation of 
covid­19 symptoms was facilitated by broad access to 
diagnostic testing in Iceland. The RT­PCR test for SARS­
CoV­2 was free of charge for both targeted testing and 
population screening, resulting in over 12% of the 
population being tested, which was higher than in any 
other country during the study period.16 As a result, we 
were able to describe the true spectrum of symptomatic 
SARS­CoV­2 infection, while previous studies were 
largely based on cohorts admitted to hospital or cases 
identified in the setting of more restrictive testing.6 12 23 
Furthermore, subgroup analysis allowed us to quantify 
the degree by which cohorts that included only 
patients admitted to hospital might overestimate the 
presence of specific symptoms—such as fever, which 
was considerably more common at symptom onset in 
patients who were later admitted to hospital (74%) 
than in patients who were never admitted (40%).
spectrum of symptoms and implications for case 
definition
The proportion of people with covid­19 who remain 
completely asymptomatic has been a focus of interest 
during the pandemic, with implications for the risk 
of disease dissemination. In the current study, 83 
individuals reported no symptoms at the time of 
diagnosis, approximately half of whom developed 
symptoms in the ensuing days. Thus, only 3.1% of cases 
diagnosed by RT­PCR remained completely symptom­
free during follow­up. However, as some degree 
of suspicion of covid­19 was needed to prompt an 
individual to be tested or to seek testing, symptomatic 
patients are likely to be overrepresented in our sample. 
The true proportion of SARS­CoV­2­positive people 
who never develop symptoms can be estimated by 
longitudinal follow­up of individuals diagnosed by 
random population screening. In the current study, 
six (30%) of the 20 individuals diagnosed by random 
population screening never developed symptoms. This 
finding is supported by a recent seroprevalence study 
in Iceland demonstrating that 44% of individuals 
with antibodies against SARS­CoV­2 had either not 
undergone RT­PCR testing or had tested negative, 
suggesting only mild or no symptoms among this 
group.17 A potential limitation of the random screening 
approach are uncertainties regarding the sensitivity 
and specificity of RT­PCR for detection of SARS­CoV­2.
Most of the included people experienced only minor 
symptoms. Only 22% of patients developed moderate 
symptoms, 8% severe symptoms, and 3.5% required 
hospital admission. The standardised prospective 
recording of clinical symptoms made it possible to 
evaluate the sensitivity of the widely used CDC21 and 
WHO20 case definitions for the diagnosis of covid­19 
throughout the course of the disease. By applying these 
definitions, we demonstrate that a substantial number 
of cases would have been missed; approximately 9% 
by the CDC criteria and 15% by the WHO criteria. The 
identification of additional 4% and 7% of cases would 
have been delayed by a median of five days and four 
days, respectively. These are concerning observations 
with immediate implications for current efforts to 
curtail the pandemic. Our data show that most patients 
have mild symptoms that may not have prompted 
table 2 | Proportion of sars-cov-2-positive people who experienced specific symptoms and symptom constellations on days 1, 3, 7, and 14 from 
symptom onset. the cumulative incidence of the specific symptoms by day 14 is shown in the last column. all values are percentages with 95% 
confidence intervals
symptoms
Proportion of people experiencing a symptom per day* cumulative incidence  
by day 14†symptom onset Day 3 Day 7 Day 14
Generalised: 83.0 (80.6 to 85.1) 78.0 (75.9 to 80.0) 65.3 (63.9 to 66.7) 40.2 (39.0 to 41.5) 92.7 (91.2 to 93.8)
 Fever ≥38°C 41.3 (36.9 to 45.8) 32.0 (29.2 to 34.9) 17.8 (16.6 to 19.2) 7.3 (6.5 to 8.2) 47.3 (44.8 to 49.8)
 Rigor, chills 31.4 (27.3 to 35.9) 23.5 (21.0 to 26.3) 12.5 (11.5 to 13.6) 5.0 (4.6 to 5.6) 41.6 (39.3 to 44.0)
 Headache 51.2 (46.8 to 55.7) 45.7 (42.4 to 48.9) 35.1 (33.5 to 36.6) 20.7 (19.6 to 21.7) 71.4 (69.0 to 73.7)
 Myalgia 54.6 (50.6 to 58.6) 44.6 (41.7 to 47.5) 26.9 (25.6 to 28.3) 10.5 (9.8 to 11.3) 61.4 (58.9 to 63.8)
 Lethargy 37.5 (33.3 to 41.9) 37.1 (34.1 to 40.3) 35.7 (34.3 to 37.2) 26.6 (25.4 to 27.8) 72.7 (70.3 to 74.7)
 Loss of appetite 23.1 (19.9 to 26.8) 22.1 (19.7 to 24.7) 19.6 (18.3 to 20.9) 11.8 (11.0 to 12.6) 44.4 (41.8 to 46.9)
Upper respiratory: 62.9 (59.1 to 66.6) 60.2 (57.4 to 63.0) 54.0 (52.5 to 55.5) 36.9 (35.7 to 38.1) 85.9 (84.1 to 87.6)
 Rhinorrhea 33.3 (29.2 to 37.8) 28.8 (26.0 to 31.7) 21.0 (19.7 to 22.4) 12.0 (11.2 to 12.9) 52.9 (50.4 to 55.3)
 Sore throat 33.7 (29.3 to 38.5) 27.6 (24.8 to 30.6) 18.0 (16.9 to 19.2) 9.7 (8.9 to 10.5) 44.1 (41.5 to 46.5)
 Dysosmia 20.5 (17.4 to 23.9) 23.0 (20.5 to 25.6) 27.3 (25.9 to 28.8) 23.2 (22.3 to 24.2) 54.5 (51.9 to 56.9)
 Dysgeusia 23.1 (19.7 to 26.7) 25.5 (22.9 to 28.4) 29.7 (28.2 to 31.2) 24.1 (23.1 to 25.0) 55.8 (53.4 to 58.0)
Lower respiratory: 63.1 (59.5 to 66.6) 61.0 (58.4 to 63.6) 56.3 (54.9 to 57.7) 42.2 (41.0 to 43.5) 79.2 (76.9 to 81.2)
 Non-productive cough 49.3 (45.2 to 53.3) 45.2 (42.3 to 48.0) 37.1 (35.7 to 38.5) 23.6 (22.5 to 24.7) 64.2 (61.8 to 66.6)
 Productive cough 13.4 (11.1 to 16.4) 14.4 (12.5 to 16.6) 16.0 (14.8 to 17.2) 14.4 (13.6 to 15.3) 35.4 (32.9 to 37.8)
 Any dyspnoea 25.2 (22.1 to 28.6) 26.0 (23.7 to 28.5) 27.0 (25.7 to 28.3) 21.0 (20.0 to 22.1) 49.5 (46.9 to 51.9)
 Dyspnoea at rest 4.5 (3.3 to 6.2) 4.6 (3.6 to 5.8) 4.5 (3.9 to 5.2) 3.6 (3.2 to 4.1) 13.7 (12.0 to 15.3)
Gastrointestinal: 30.0 (26.0 to 34.4) 26.9 (24.1 to 29.9) 21.0 (19.6 to 22.5) 11.1 (10.3 to 12.0) 48.2 (45.7 to 50.6)
 Nausea 13.0 (10.6 to 15.7) 11.8 (10.2 to 13.6) 9.6 (8.7 to 10.5) 5.1 (4.6 to 5.6) 25.0 (22.9 to 27.2)
 Vomiting 3.4 (2.2 to 5.3) 2.7 (1.9 to 3.8) 1.7 (1.3 to 2.2) 0.9 (0.6 to 1.3) 4.8 (3.9 to 5.9)
 Abdominal pain 11.1 (8.7 to 14.0) 9.2 (7.6 to 11.0) 6.3 (5.6 to 7.2) 3.8 (3.4 to 4.4) 22.3 (20.3 to 24.2)
 Diarrhoea 13.7 (11.1 to 16.9) 12.5 (10.6 to 14.6) 10.1 (9.2 to 11.1) 6.0 (5.4 to 6.6) 28.0 (25.7 to 30.2)
*The predicted proportion of SARS-CoV-2-positive individuals who experience a symptom at the designated day from symptom onset, as estimated by multiple imputation logistic regression.
†The cumulative incidence of a symptom by day 14 from symptom onset, as estimated by the parametric cure-mixture model.
copyright.













J: first published as 10.1136/bm
j.m







8 doi: 10.1136/bmj.m4529 | BMJ 2020;371:m4529 | the bmj
the consideration of covid­19 by either patients or 
healthcare providers in more resource­limited settings, 
and indicate a need for revising and widening the CDC 
and WHO case definitions to increase their sensitivity.
comparison with other studies
Symptoms observed among patients with mild 
forms of covid­19 have previously been examined 
in a multicentre European study of 1420 people 
with positive RT­PCR test results who answered a 
questionnaire.10 Severely ill patients were excluded, 
and the remaining cohort was predominantly female 
(68%), young (94% <60 years old), and biased towards 
healthcare workers (31% of the group).10 While these 
results are not easily generalisable to the entire 
population, the investigators found that only 7% of 
patients required hospital admission,10 compared with 
3.5% in the present study. Headache, loss of smell, and 
nasal obstruction were the most common symptoms 
identified.10 Although these symptoms were also 
frequently identified in our cohort, we found cough 
and myalgia to be more common. The predominance 
of loss of smell identified in the aforementioned study 
agrees with our observation that olfactory symptoms 
are most common in the younger age groups.10
We found that slightly less than half of patients 
developed fever during the course of the disease, 
already present in 85% of those by day 3. This is 
consistent with the study by Lechien et al, who noted 
fever ≥38.0°C in 45.4% of cases,10 while it is higher 
than what was reported by Guan et al (21.7%)5 and 
Goyal et al (25%).12 A meta­analysis by Sun et al found 
that 89% of covid­19 patients had a fever ≥37.3°C,6 
but this definition of fever is rarely used in clinical 
practice. Over the follow­up period, 70% of patients in 
our study experienced cough, which is consistent with 
the findings of Lechien et al, who observed cough in 
63% of cases.10 In total, 52% of patients reported any 
dyspnoea and only 14% described dyspnoea at rest 
during the course of the disease. The reported incidence 
of dyspnoea ranges from 22% to 49%,7 10 24 but most 
previous studies do not differentiate between dyspnoea 
at rest and dyspnoea on exertion. Gastrointestinal 
symptoms were common in our study, reported by 
almost half of patients at some point during the first 
14 days. Abdominal pain (22%) and diarrhoea (28%) 
were frequent, as in previous studies.12 25 Interestingly, 
although a quarter of patients experienced nausea, 
vomiting was rare.
Our findings indicate a lower rate of hospital 
admissions and mortality in Iceland compared with 
many other countries. The reasons for these disparate 
outcomes are likely multifactorial. Iceland has a 
relatively young population, with 85.8% under 65 
years old, compared with 77.1% in Italy, 80.6% in 
Spain, 81.6% in the UK, and 83.5% in the US.26 27 The 
relatively young population, in addition to a strong 
emphasis on limiting the exposure of elderly and 
multimorbid individuals, resulted in a low median age 
of confirmed covid­19 cases of 40 years (IQR 26­53) in 
Iceland compared with 51 years (IQR 36­65) among all 
cases reported to the WHO28 and 48 years (IQR 33­63) 
in the US.29 Hence, the strategy to protect susceptible 
individuals seems to have been effective. In the recent 
seroprevalence study in Iceland, the infection fatality 
rate was estimated to be 0.3%.17 Different rates of 
specific risk factors for inferior outcomes in covid­19 
are unlikely to explain this difference as they seem 
to have a similar distribution in Iceland as in other 
countries. For instance, 29% of Icelandic adults have 
hypertension30 and 27% are obese.31 Nevertheless, 
these differences and the homogenous population in 
Iceland may limit the generealisability of our findings 
to other nations and geographical areas.
strengths and limitations
This study does have limitations. We do not have 
information on SARS­CoV­2­negative individuals, and 
therefore the baseline rate of symptoms that resemble 
those of covid­19 in the population is unknown. 
The rate of such symptoms in the community is not 
zero, and therefore some of the symptoms attributed 
to SARS­CoV­2 in this study may be due to other 
causes. However, this is unlikely to affect the overall 
interpretation of our findings as there was a strong 
temporal relation between the diagnosis and the onset 
and resolution of symptoms. It is also noteworthy that, 











































Fig 3 | cumulative incidence and proportion of sars-cov-2-positive individuals who 
experienced cough, dyspnoea, fever, and gastrointestinal symptoms by days from 
symptom onset. the parametric cure-mixture estimate of the cumulative incidence is 
illustrated in the upper panel with the 95% confidence interval shown as a shaded area. 
the lower panel depicts the logistic regression estimate of the proportion of infected 
individuals who experience each symptom by day (95% confidence intervals shown as 
a shaded area)
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cases diagnosed before the implementation of the 
standardised clinical data entry form were excluded 
from the analysis of symptom development, represen­
ting 11% of all SARS­CoV­2­positive cases in Iceland. 
The date of implementation of the standardised 
data entry form was not influenced by the clinical 
characteristics of the patients being diagnosed, and 
therefore should not introduce bias. Furthermore, the 
demographics and clinical characteristics of excluded 
cases were largely comparable to those that were 
included in the study. 
Another limitation is that daily standardised 
documentation of symptoms was not available du­
ring hospital admission. This could conceivably 
lead to an underestimation of severe symptoms such 
as dyspnoea. However, only 3.5% of the included 
patients were admitted to hospital, and symptoms 
before hospitalisation were included in the analysis. 
It is important to note that the data were based on 
self reported symptoms via telephone calls. This 
shortcoming is mitigated by the fact that experienced 
nurses and physicians conducted the interviews. 
Finally, our study was concerned with the 
symptomatology of the acute phase of covid­19. It 
has become apparent that patients may experience 
prolonged symptoms after their initial infection.32 
Telehealth monitoring was discontinued after the 
resolution of the acute illness, and we therefore cannot 
characterise the nature of long term symptoms of 
covid­19. 
A principal strength of the study is its population 
based approach, which included all confirmed cases in 
the country during the study period regardless of their 
need for medical care.
conclusions
This report describes the symptomatology and clinical 
severity of covid­19 in Iceland. The incidence of 
covid­19 was high due to extensive testing of both 
symptomatic and asymptomatic individuals, while 
disease severity was lower than previously reported. 
Symptoms such as fever and dyspnoea were less 
common than has been observed in earlier studies. 
Our findings suggest that both the CDC and WHO case 
definitions of covid­19 lack sensitivity and miss a 
substantial proportion of patients, including patients 
who later develop severe disease.
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